TrialBlood2019

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.

Robert Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.